<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Liver and <z:e sem="disease" ids="C0153676" disease_type="Neoplastic Process" abbrv="">lung metastases</z:e> are the predominant cause of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>)-related mortality </plain></SENT>
<SENT sid="1" pm="."><plain>Chemokine-receptor pairs have a critical role in determining the metastatic progression of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Our hypothesis was that disruption of CXCR7/CXCR7 ligands axis could lead to a decrease in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">Primary tumours</z:e> and metastatic tissues from patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> were tested for the expression of CXCR7 and its ligands </plain></SENT>
<SENT sid="4" pm="."><plain>Relevance of CXCR7/CXCR7 ligands for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> was then investigated in mice using small pharmacological CXCR7 <z:chebi fb="68" ids="48706">antagonists</z:chebi> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell lines of human and murine origins, which - injected into mice - enable the development of lung and <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Following injection of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells, mice treated daily with CXCR7 <z:chebi fb="68" ids="48706">antagonists</z:chebi> exhibited a significant reduction in <z:e sem="disease" ids="C0153676" disease_type="Neoplastic Process" abbrv="">lung metastases</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>However, CXCR7 <z:chebi fb="68" ids="48706">antagonists</z:chebi> failed to reduce the extent of <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Moreover, there were subtle differences in the expression of CXCR7 and its ligands between lung and <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: Our study suggests that the activation of CXCR7 on <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> blood vessels by its ligands may facilitate the progression of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> within lung but not within liver </plain></SENT>
<SENT sid="9" pm="."><plain>Moreover, we provide evidence that targeting the CXCR7 axis may be beneficial to limit <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> from <z:hpo ids='HP_0003003'>colon cancer</z:hpo> within the lungs </plain></SENT>
</text></document>